☆ 4.6 Review

Implications of recent neoadjuvant clinical trials on the future practice of radiotherapy in locally advanced rectal cancer

WORLD JOURNAL OF GASTROENTEROLOGY (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Oncology

Neoadjuvant Therapy in the Post-German Rectal Trial Era: Making Sense in the Absence of Consensus

Caressa Hui et al.

Summary: Trimodality therapy has shown excellent outcomes for locally advanced rectal cancer. Recent efforts aim to improve distant control and quality of life by using total neoadjuvant therapy and a watch-and-wait approach. This has raised uncertainties in the neoadjuvant treatment paradigm, which requires shared decision-making with patients.

PRACTICAL RADIATION ONCOLOGY (2023)

Add to Collection

Article Oncology

Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study)

X. Serra-Aracil et al.

Summary: This study compared the effectiveness of chemoradiotherapy combined with minimally invasive surgery and traditional surgery in the treatment of T2-T3ab,N0,M0 rectal cancer. The study found that chemoradiotherapy combined with minimally invasive surgery can reduce postoperative complications and hospitalization rates, and achieve a high rate of pathological complete response.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Review Oncology

Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach?

Luis Cabezon-Gutierrez et al.

Summary: This review summarizes the evidence from studies on the efficacy and tolerability of neoadjuvant immunotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) Locally Advanced Rectal Cancer (LARC). A total of 92 studies were obtained, but only 9 were included in the final analysis, showing overall response rates of 100%. The promising results suggest the potential to explore alternative treatments for these patients in the future.

EJSO (2023)

Add to Collection

Article Oncology

Construction and Evaluation of Nomogram for Hematological Indicators to Predict Pathological Response after Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Keli Wang et al.

Summary: In this retrospective study, prediction models were developed to evaluate the association between hematological indexes, their changes during neoadjuvant chemoradiotherapy (NCRT), and tumor pathological response in patients with locally advanced rectal cancer. The study found that low preoperative CEA level, young age, high tumor distance from the anal verge, the maintenance of circulating lymphocyte level, and a decreased platelet level after NCRT were important factors for favorable outcomes after NCRT. A nomogram prediction model with good discrimination and consistency was developed to predict pathological responses after NCRT.

JOURNAL OF GASTROINTESTINAL CANCER (2023)

Add to Collection

Article Oncology

Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer

Hideaki Bando et al.

Summary: The study suggests that consolidation treatment with nivolumab after CRT can increase the pCR rate in patients with rectal cancer. PD-L1 expression and an elevated CD8/eTreg ratio are positive predictors in patients with MSS rectal cancer.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial

Emmanouil Fokas et al.

Summary: This study reported the long-term results of total neoadjuvant therapy in locally advanced rectal cancer, showing that chemoradiotherapy followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, quality of life, or stool incontinence, and is proposed as the preferred sequence for total neoadjuvant therapy if organ preservation is a priority.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)

Yaqi Wang et al.

Summary: The TORCH trial aims to investigate whether short-course radiotherapy (SCRT) combined with chemotherapy and Toripalimab can achieve better complete response rates, good tolerance, and prognosis in patients with locally advanced rectal cancer (LARC). This is the first clinical trial to compare the efficacy of induced immunotherapy and consolidative immunotherapy based on the total neoadjuvant therapy (TNT) strategy.

BMC CANCER (2022)

Add to Collection

Article Oncology

Clinical Complete Response in Patients With Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Nonoperative Management

Re- Chin et al.

Summary: Short-course radiation therapy followed by consolidation chemotherapy may be a feasible organ preservation strategy in rectal cancer. Nonoperative management (NOM) showed better outcomes in terms of regional control, distant metastasis-free survival, disease-free survival, and overall survival compared to surgery in patients with clinical complete response (cCR), and it was also found to be safe.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection

Article Oncology

Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)

Jing Jin et al.

Summary: This study aimed to compare the efficacy of preoperative short-term radiotherapy followed by chemotherapy with a standard schedule of long-term chemoradiotherapy in patients with locally advanced rectal cancer. The results showed that the short-term radiotherapy and chemotherapy regimen was non-inferior to the standard regimen in terms of 3-year disease-free survival and had better overall survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

Julio Garcia-Aguilar et al.

Summary: This study demonstrates that organ preservation is achievable in patients with locally advanced rectal cancer treated with total neoadjuvant therapy, without a decrease in survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Association of neutrophil-to-lymphocyte ratio, radiotherapy fractionation/technique, and risk of development of distant metastasis among patients with locally advanced rectal cancer

Gowoon Yang et al.

Summary: The study investigated the prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in locally advanced rectal cancer (LARC) patients and whether modifiable factors in radiotherapy (RT) influenced the NLR. The results showed that increased NLR after neoadjuvant RT is associated with increased distant metastasis risk and poor survival outcome in patients with LARC. Moreover, high NLR following RT is directly related to RT fractionation, delivery modality, and tumor characteristics.

RADIATION ONCOLOGY (2022)

Add to Collection

Article Oncology

STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?

Simon Parkinson Bach et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

How We Treat Localized Rectal Cancer-An Institutional Paradigm for Total Neoadjuvant Therapy

Falk Roeder et al.

Summary: The treatment of locally advanced rectal cancer has changed significantly, with the introduction of total neoadjuvant therapy, non-operative management for patients with clinical complete responses after neoadjuvant treatment, and upfront immunotherapy for patients with MSI-high/dMMR tumors.

CANCERS (2022)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer

Andrea Cercek et al.

Summary: This study found that mismatch repair-deficient, locally advanced rectal cancer is highly sensitive to PD-1 blockade. Additionally, no adverse events of grade 3 or higher have been reported, and no cases of progression or recurrence have been observed. Longer follow-up is needed to assess the duration of response.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Current Practice Patterns in Locally Advanced Rectal Cancer at Academic Institutions: A National Survey Among Radiation Oncologists, Medical Oncologists, and Colorectal Surgeons

Trudy C. Wu et al.

Summary: The treatment landscape of rectal cancer has shifted towards a total neoadjuvant approach (TNT) for most locally advanced tumors, with a preference for conventionally fractionated long-course radiotherapy. Non-operative management after TNT has gained acceptance, transforming rectal cancer from a classically perceived surgical disease. Academic specialists now infrequently recommend the traditional regimen of long-course chemoradiation, surgery, and adjuvant chemotherapy.

CLINICAL COLORECTAL CANCER (2022)

Add to Collection

Article Oncology

Preliminary Results of a Prospective Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Y. Tang et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection

Article Oncology

Short-Course Radiotherapy Based Total Neoadjuvant Therapy Combined with Toripalimab for Locally Advanced Rectal Cancer: Preliminary Findings from a Randomized, Prospective, Multicenter, Double-Arm, Phase II Trial (TORCH)

Y. Wang et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection

Article Oncology

Rectal Cancer, Version 2.2022

Al B. Benson et al.

Summary: This article, excerpted from the NCCN Guidelines for Rectal Cancer, focuses on the management of malignant polyps and resectable nonmetastatic rectal cancer. The guidelines have been updated to reflect new data supporting total neoadjuvant therapy, expanded recommendations for radiation therapy, and a nonoperative management technique for patients with a complete response to neoadjuvant therapy.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Oncology

Peripheral Lymphocyte Counts and Lymphocyte-Related Inflammation Indicators During Radiotherapy for Pelvic Malignancies: Temporal Characterization and Dosimetric Predictors

Xiaoyong Xiang et al.

Summary: This study aims to identify dosimetric predictors of lymphocytopenia and analyze the changing trend of peripheral lymphocyte counts and lymphocyte-related inflammatory indicators in patients undergoing pelvic radiotherapy. The results show that pelvic radiotherapy has a significant and long-lasting impact on lymphocyte counts and related inflammatory indicators, and reducing radiation exposure to the pelvic bone can help prevent severe lymphocytopenia.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2022)

Add to Collection

Review Oncology

Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis

Chun-Kai Liao et al.

Summary: This systematic review and meta-analysis found that neoadjuvant short course radiotherapy followed by consolidation chemotherapy could effectively improve tumor response and oncological outcomes for locally advanced rectal cancer. The treatment had comparable safety and toxicity profiles to conventional chemoradiotherapy.

CURRENT ONCOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation

Arthur Affleck et al.

Summary: There has been a significant increase in the incidence of rectal cancer, leading to a focus on early detection and optimal treatment. This review highlights the major trials that have revolutionized rectal cancer management and improved outcomes. The current standard of care for non-metastatic locally advanced rectal cancer includes preoperative chemoradiation, total mesorectal excision, and adjuvant therapy.

ANNALS OF GASTROENTEROLOGY (2022)

Add to Collection

Article Oncology

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

Jaume Capdevila et al.

Summary: The management of localized rectal cancer requires a multidisciplinary approach for optimal outcomes and reduced morbidity. The best sequential strategy for surgery, radiotherapy and chemotherapy is still a challenge for locally advanced rectal cancer. Recent international phase III studies have suggested total neoadjuvant therapy as a potential new standard of care for high risk rectal cancers, but the optimal schedule is not yet well defined.

CLINICAL & TRANSLATIONAL ONCOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses

Miao Yu et al.

Summary: The study systematically evaluated the clinical efficacy of a long interval (8 weeks) between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer. The results showed that a longer interval improved the pathologic complete response rate but had no significant impact on clinical efficacy or long-term prognosis.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2022)

Add to Collection

Review Oncology

Neoadjuvant Radiotherapy Dose Escalation in Locally Advanced Rectal Cancer: a Systematic Review and Meta-analysis of Modern Treatment Approaches and Outcomes

N. Hearn et al.

Summary: This study aimed to investigate the impact of radiation dose escalation on pCR rates and clinical outcomes in locally advanced rectal cancer patients undergoing neoadjuvant therapy. The results showed that moderate dose escalation (54-60 Gy) in modern inverse-planning studies was associated with high pCR rates without increasing the risk of severe toxicity. However, no significant predictor of pCR was identified in regression analysis.

CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Single High-Dose Radiation Enhances Dendritic Cell Homing and T Cell Priming by Promoting Reactive Oxygen Species-Induced Cytoskeletal Reorganization

Ziqi Zhou et al.

Summary: This study systematically examined the dose effect of radiation therapy on the in vivo homing and distribution of bone marrow-derived dendritic cells using noninvasive imaging. The results showed that radiation did not directly cause cellular apoptosis or necrosis in DCs, but induced mitochondrial damage and upregulation of certain receptors. Higher radiation doses (>= 5 Gy) significantly increased the homing ability of DCs to lymphoid tissues, and this improvement was associated with reactive oxygen species accumulation. Enhanced T cell activation was also observed in mice inoculated with higher radiation dose-treated DCs, indicating the advantages of >= 5 Gy radiation in facilitating DC homing and T cell priming.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection

Article

Watch-and-wait Management for Rectal Cancer After Clinical Complete Response to Neoadjuvant Therapy

Jonathan B. Yuval et al.

Advances in Surgery (2021)

Add to Collection

Article Oncology

Long-Term Results of a Prospective Phase 2 Study on Volume De-Escalation in Neoadjuvant Chemoradiotherapy of Rectal Cancer

Michele Fiore et al.

Summary: The study evaluated whether neoadjuvant chemoradiotherapy with reduced treatment volumes due to the exclusion of elective pelvic nodal irradiation is a feasible strategy for selected patients with locally advanced rectal cancer. Results showed that de-escalation of radiation therapy target volume reduces gastrointestinal side effects without compromising efficacy, leading to improved local control rate and overall survival.

PRACTICAL RADIATION ONCOLOGY (2021)

Add to Collection

Article Oncology

Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline

Jennifer Y. Wo et al.

Summary: This guideline provides evidence-based recommendations for neoadjuvant radiation therapy in the treatment of localized rectal cancer, emphasizing the importance of preoperative RT and proposing specific treatment options for different patient populations. For rectal cancer patients, a comprehensive treatment strategy including chemotherapy before and after RT is recommended, with nonoperative management considered in cases of clinical complete response.

PRACTICAL RADIATION ONCOLOGY (2021)

Add to Collection

Article Oncology

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer et al.

Summary: The RAPIDO trial aimed to reduce systemic relapses in locally advanced rectal cancer through short-course radiotherapy, chemotherapy, and delayed surgery. Results showed a decreased probability of disease-related treatment failure in the experimental group compared to standard care, with diarrhea being the most common adverse event and neurological toxicity being prominent in the standard care group during adjuvant chemotherapy.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer

Incheol Seo et al.

Summary: The study found that neoadjuvant chemoradiation therapy (CRT) significantly enriched the immune response in locally advanced rectal cancer (LARC) tissues and affected related immunogenic effects. Furthermore, CRT can lead to downregulation of MMR system-related genes and an increase in tumor mutational burden and proportions of immune-related cells in LARC tissues.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Oncology

Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Metaanalysis of Oncological and Operative Outcomes

Joseph C. Kong et al.

Summary: The study highlights the favorable immediate and intermediate oncological outcomes with total neoadjuvant therapy in locally advanced rectal cancer, showing higher complete pathological response rate, lower distant recurrence rate, and better 3-year disease-free survival and overall survival compared to standard neoadjuvant chemoradiotherapy.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial

Hyun Kim et al.

Summary: This study evaluated short-course radiation therapy followed by chemotherapy as a nonoperative treatment modality for rectal adenocarcinoma, showing high clinical complete response rate, intact anorectal function, and no severe late effects.

CLINICAL COLORECTAL CANCER (2021)

Add to Collection

Article Oncology

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer

Zhenyu Lin et al.

Summary: The study found that preoperative short-course radiotherapy combined with CAPOX and camrelizumab followed by delayed surgery showed a favorable pathological complete response rate in locally advanced rectal cancer patients, especially in proficient MMR tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Medicine, General & Internal

Neoadjuvant radiotherapy dose escalation for locally advanced rectal cancers in the new era of radiotherapy: A review of literature

Durim Delishaj et al.

Summary: The standard treatment for locally advanced rectal cancers is neoadjuvant chemoradiotherapy followed by surgery. Studies have shown benefits of radiotherapy dose escalation for tumor downstaging, but there is limited research on dose escalation using innovative techniques for LARC (T3-4 or N1-2). A review of literature suggests that neoadjuvant radiotherapy dose escalation using innovative techniques can achieve higher rates of pCR in LARC, but EQD2 doses greater than 58.9 Gy are associated with increased risk of surgical complications.

WORLD JOURNAL OF CLINICAL CASES (2021)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy et al.

Summary: In patients with cT3 or cT4 M0 rectal cancer, intensifying chemotherapy with FOLFIRINOX before preoperative chemoradiotherapy significantly improved disease-free survival outcomes and reduced neurotoxicity. Thus, the PRODIGE 23 results have the potential to impact clinical practice.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Effect of Pelvic Bone Marrow Sparing Intensity Modulated Radiation Therapy on Acute Hematologic Toxicity in Rectal Cancer Patients Undergoing Chemo-Radiotherapy

Wei Huang et al.

Summary: This study aimed to explore feasible dosimetric constraints for pelvic bone marrow (PBM) in rectal cancer patients undergoing chemo-radiotherapy. The results showed that applying PBM dosimetric constraints can significantly reduce radiation dose to PBM and lower the incidence of acute hematological toxicity.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study

A. Shamseddine et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

R-IMMUNE interim analysis: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radiochemotherapy in a preoperative setting for patients with localized rectal cancer

J. Carrasco et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Oncology

Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition

Elliot H. Akama-Garren et al.

Summary: Immune checkpoint inhibitors have shown durable responses in some cancer patients, but many do not respond, leading to interest in combining immunotherapy with other treatments. Preclinical evidence supports the potential synergy between immunotherapy and radiation therapy in modulating the tumor microenvironment and immune responses against tumors. Prospective clinical trials are underway to investigate the safety, efficacy, and potential toxicities associated with combining immunotherapy and radiation therapy.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection

Meeting Abstract Oncology

Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study.

Lisa Salvatore et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

Catherine R. Hanna et al.

Summary: The PRIME-RT trial aims to investigate the impact of adding immunotherapy to neoadjuvant radiotherapy and chemotherapy for LARC patients in order to improve complete response rates and stoma-free survival.

RADIATION ONCOLOGY (2021)

Add to Collection

Article Oncology

Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial

Osama E. Rahma et al.

Summary: The study evaluated the addition of pembrolizumab during and after neoadjuvant chemoradiotherapy in rectal cancer patients, showing no significant differences in NAR score, pathological complete response rate, and other outcomes between the two groups.

JAMA ONCOLOGY (2021)

Add to Collection

Review Oncology

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Hiro Sato et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy

Philippe Lambin et al.

SEMINARS IN RADIATION ONCOLOGY (2020)

Add to Collection

Article Oncology

Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma

Ali Shamseddine et al.

BMC CANCER (2020)

Add to Collection

Article Oncology

Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer

Lukasz Kuncman et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2020)

Add to Collection

Article Oncology

Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma

Ali Shamseddine et al.

RADIATION ONCOLOGY (2020)

Add to Collection

Article Oncology

A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy

Wonmo Sung et al.

RADIOTHERAPY AND ONCOLOGY (2020)

Add to Collection

Article Oncology

Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy

Dawei Chen et al.

RADIOTHERAPY AND ONCOLOGY (2020)

Add to Collection

Article Oncology

Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy

Zachary S. Buchwald et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Medicine, Research & Experimental

Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance)

Deborah Schrag et al.

CLINICAL TRIALS (2019)

Add to Collection

Article Oncology

Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study

B. Cisel et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12

Emmanouil Fokas et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial

Johan Erlandsson et al.

RADIOTHERAPY AND ONCOLOGY (2019)

Add to Collection

Article Oncology

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

Mathieu Grapin et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Yanhong Deng et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

Yong Sang Hong et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Pharmacology & Pharmacy

Immune mechanisms mediating abscopal effects in radioimmunotherapy

Maria E. Rodriguez-Ruiz et al.

PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection

Article Oncology

Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients

C. Yuan et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy

Ariel E. Marciscano et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Review Oncology

A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors

Bhanu Prasad Venkatesulu et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)

Add to Collection

Article Oncology

Dose Escalation Using Contact X-ray Brachytherapy After External Beam Radiotherapy as Nonsurgical Treatment Option for Rectal Cancer: Outcomes From a Single-Center Experience

Arthur Sun Myint et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)

Add to Collection

Review Oncology

Rectal Cancer, Version 2.2018 Clinical Practice Guidelines in Oncology

Al B. Benson et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)

Add to Collection

Article Medicine, General & Internal

Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study

Maxime J. M. van der Valk et al.

LANCET (2018)

Add to Collection

Article Oncology

Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer

Jian L. Campian et al.

CANCER INVESTIGATION (2018)

Add to Collection

Article Oncology

Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy

Dengbo Ji et al.

CANCER IMMUNOLOGY RESEARCH (2018)

Add to Collection

Article Oncology

Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity

Chan Woo Wee et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States

Yvonne M. Mowery et al.

CANCER (2017)

Add to Collection

Article Oncology

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial

Johan Erlandsson et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Aaron M. Goodman et al.

MOLECULAR CANCER THERAPEUTICS (2017)

Add to Collection

Article Multidisciplinary Sciences

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

Giovanni Germano et al.

NATURE (2017)

Add to Collection

Article Multidisciplinary Sciences

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Alexander C. Huang et al.

NATURE (2017)

Add to Collection

Article Multidisciplinary Sciences

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

Claire Vanpouille-Box et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Oncology

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors

Adam Diehl et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?

Jennifer B. Goldstein et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer

Bong Kyung Bae et al.

RADIATION ONCOLOGY JOURNAL (2017)

Add to Collection

Article Oncology

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

R. Glynne-Jones et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Review Oncology

Dosimetric predictors of treatment-related lymphopenia induced by palliative radiotherapy: predictive ability of dose-volume parameters based on body surface contour

Tetsuo Saito et al.

RADIOLOGY AND ONCOLOGY (2017)

Add to Collection

Article Oncology

Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study

K. Bujko et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Oncology

Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen

Angelita Habr-Gama et al.

RADIATION ONCOLOGY (2016)

Add to Collection

Article

Short-course Versus Long-course Preoperative Radiotherapy plus Delayed Surgery in the Treatment of Rectal Cancer: a Meta-analysis

Shi-Xin Liu et al.

Asian Pacific Journal of Cancer Prevention (2015)

Add to Collection

Article Oncology

Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

J. Joshua Smith et al.

BMC CANCER (2015)

Add to Collection

Review Oncology

Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data

Anne J. Breugom et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

Claus Roedel et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial

A. J. Breugom et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Oncology

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

Simon J. Dovedi et al.

CANCER RESEARCH (2014)

Add to Collection

Article Oncology

Lymphopenia Association With Gross Tumor Volume and Lung V5 and Its Effects on Non-Small Cell Lung Cancer Patient Outcomes

Chad Tang et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)

Add to Collection

Article Oncology

Long-Term Results of a Randomized Trial in Locally Advanced Rectal Cancer: No Benefit From Adding a Brachytherapy Boost

Ane L. Appelt et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)

Add to Collection

Article Medicine, Research & Experimental

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice

Liufu Deng et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

Add to Collection

Article Oncology

Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04

Michael J. O'Connell et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Oncology

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial

Yong Sang Hong et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Oncology

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study

Jean-Francois Bosset et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Oncology

Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer - the RAPIDO trial

Per J. Nilsson et al.

BMC CANCER (2013)

Add to Collection

Article Oncology

The Etiology of Treatment-related Lymphopenia in Patients with Malignant Gliomas: Modeling Radiation Dose to Circulating Lymphocytes Explains Clinical Observations and Suggests Methods of Modifying the Impact of Radiation on Immune Cells

Susannah Yovino et al.

CANCER INVESTIGATION (2013)

Add to Collection

Article Oncology

Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy

Ane L. Appelt et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Dosimetric comparison between IMRT delivery modes: Step-and-shoot, sliding window, and volumetric modulated arc therapy - for whole pelvis radiation therapy of intermediate-to-high risk prostate adenocarcinoma

Tania De La Fuente Herman et al.

JOURNAL OF MEDICAL PHYSICS (2013)

Add to Collection

Article Oncology

Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

Jean-Pierre Gerard et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years

Rolf Sauer et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

DISTRIBUTION OF PROLIFERATING BONE MARROW IN ADULT CANCER PATIENTS DETERMINED USING FLT-PET IMAGING

James A. Hayman et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)

Add to Collection

Article Oncology

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

Carlo Aschele et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Pathology

Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma

Fei Bao et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)

Add to Collection

Article Hematology

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

Youjin Lee et al.

BLOOD (2009)

Add to Collection

Article Oncology

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

M. Zahidunnabi Dewan et al.

CLINICAL CANCER RESEARCH (2009)

Add to Collection

Article Oncology

ELECTIVE CLINICAL TARGET VOLUMES FOR CONFORMAL THERAPY IN ANORECTAL CANCER: A RADIATION THERAPY ONCOLOGY GROUP CONSENSUS PANEL CONTOURING ATLAS

Robert J. Myerson et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)

Add to Collection

Article Medicine, General & Internal

Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

David Sebag-Montefiore et al.

LANCET (2009)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy

Steven D. Allen et al.

AMERICAN JOURNAL OF ROENTGENOLOGY (2007)

Add to Collection

Article Oncology

Definition and delineation of the clinical target volume for rectal cancer

Sarah Roels et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)

Add to Collection

Article Surgery

Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy - Long-term results

A Habr-Gama et al.

ANNALS OF SURGERY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.